	Application No.	Applicant(s)
Notice of Allowability		
	10/775,443 Examiner	BISACCHI ET AL. Art Unit
	Charanjit S. Aulakh	1625
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to <u>Paper filed on Feb. 3, 2006</u> .		
2. The allowed claim(s) is/are <u>1-21,23,28-30 and 32-46</u> .		
 3. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) ☐ All b) ☐ Some* c) ☐ None of the: 1. ☐ Certified copies of the priority documents have been received. 		
2. Certified copies of the priority documents have been received in Application No		
 3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)). * Certified copies not received: 		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) hereto or 2) to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s)		
1. Notice of References Cited (PTO-892)	5. Notice of Informal Page 1	atent Application (PTO-152)
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. Interview Summary	
 3. Information Disclosure Statements (PTO-1449 or PTO/SB/08 Paper No./Mail Date 11/23/2005 4. Examiner's Comment Regarding Requirement for Deposit of Biological Material 	Paper No./Mail Date 8), 7. ⊠ Examiner's Amendm	
	8. Examiner's Stateme	nt of Reasons for Allowance
	9.	

Application/Control Number: 10/775,443 Page 2

Art Unit: 1625

DETAILED ACTION

1. According to paper filed on Nov. 23, 2005, the applicants have canceled claims 24-27; amended claims 1-12 and 19 and furthermore, have added new claims 28-31. In a subsequent supplemental amendment filed on Feb. 3, 2006, the applicants have canceled claim 31; amended claims 21-23 and furthermore, have added new claims 32-46.

2. Claims 1-23, 28-30 and 32-46 are now pending in the application.

EXAMINER'S AMENDMENT

3. The following amendment is pursuant to a telephone conversation with the applicant's attorney, Ms. Jing G. Sun on Feb. 16, 2006. The following changes have been made in claims:

Cancel claim 22.

In claim 2, page 5, lines 11-12 from top, <u>delete</u> ----R16 is alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, heteroaryl, cycloalkyl, or heterocyclo;------.

In claim 23, <u>delete</u> the whole text and rewrite it as ----- A method according to claim 21, wherein the thrombosis is selected from the group consisting of arterial thrombosis, venous thrombosis, deep vein thrombosis and cerebral thrombosis -----.

4. Claims 1-21, 23, 28-30 and 32-46, renumbered as claims 1-40, are allowed.

Application/Control Number: 10/775,443 Page 3

Art Unit: 1625

5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Charanjit S. Aulakh whose telephone number is (571)272-0678. The examiner can normally be reached on Monday through Friday, 8:30 A.M. to 5:00 P.M..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Cecilia Tsang can be reached on (571)272-0562. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Charanjit S. Aulakh
Primary Examiner
Art Unit 1625